Charles River Acquires Distributed Bio
The past two years spent in partnership with Distributed Bio have resulted in some groundbreaking science, collaboration, and discoveries for our clients, most recently in the therapeutic antibody space.
Having exclusive access to Distributed Bio's revolutionary platform for therapeutic antibody discovery and optimization has given our sponsors a leg up on the competition, allowing them to identify unique, proprietary antibody hits against even the most challenging targets. Combined with the expertise and insight offered by our multidisciplinary team of discovery scientists, the SuperHuman antibody library and Tumbler optimization technology has helped clients to shave months off their project timelines.
Now officially part of the Charles River family, Distributed Bio adds dedicated facilities and scientific resources to our existing regional support of the South San Francisco biotech hub and early discovery clients worldwide. The acquisition ensures that our clients continue to reap the lasting benefits of the scientific exchange fostered between our organizations over the course of partnership. We are honored to welcome our pioneering colleagues into the fold; together, we will continue to raise the bar for large molecule and antibody drug discovery and development as a single organization offering seamless service from hit ID to IND.
Have an antibody or large molecule discovery project you’d like to discuss?